Guardant Health Inc
GH110.170USD
+1.430+1.32%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
13.77BMarket Cap
LossP/E TTM
More Details of Guardant Health Inc Company
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Guardant Health Inc Info
Ticker SymbolGH
Company nameGuardant Health Inc
IPO dateOct 04, 2018
CEOTalasaz (Amirali)
Number of employees1999
Security typeOrdinary Share
Fiscal year-endOct 04
Address3100 Hanover Street
CityPALO ALTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94304
Phone18556988887
Websitehttps://guardanthealth.com/
Ticker SymbolGH
IPO dateOct 04, 2018
CEOTalasaz (Amirali)
Company Executives of Guardant Health Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.39M
+13209.00%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
58.93K
+13920.00%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.71K
+9057.00%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
31.84K
+11845.00%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+6674.00%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.32K
+43.00%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
16.08K
+10416.00%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.18K
-100.00%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
7.99K
+134.00%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.39M
+13209.00%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
58.93K
+13920.00%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.71K
+9057.00%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
31.84K
+11845.00%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
+6674.00%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.32K
+43.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
249.44M
94.06%
International
15.76M
5.94%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.22%
BlackRock Institutional Trust Company, N.A.
6.65%
Baillie Gifford & Co.
3.98%
Capital International Investors
3.64%
Invesco Advisers, Inc.
3.60%
Other
72.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.22%
BlackRock Institutional Trust Company, N.A.
6.65%
Baillie Gifford & Co.
3.98%
Capital International Investors
3.64%
Invesco Advisers, Inc.
3.60%
Other
72.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.27%
Investment Advisor/Hedge Fund
30.42%
Hedge Fund
14.68%
Individual Investor
4.06%
Sovereign Wealth Fund
1.77%
Research Firm
1.76%
Bank and Trust
1.57%
Pension Fund
0.81%
Family Office
0.05%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
776
125.36M
97.30%
-17.21M
2025Q3
765
128.93M
100.07%
-13.82M
2025Q2
759
134.16M
107.59%
-14.14M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
2023Q3
867
117.78M
100.31%
-19.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
11.88M
9.22%
-260.03K
-2.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.57M
6.65%
+175.77K
+2.09%
Sep 30, 2025
Baillie Gifford & Co.
5.13M
3.98%
+317.91K
+6.61%
Sep 30, 2025
Capital International Investors
4.69M
3.64%
-287.22K
-5.77%
Sep 30, 2025
Invesco Advisers, Inc.
4.64M
3.6%
+1.24M
+36.43%
Sep 30, 2025
Deep Track Capital LP
4.15M
3.22%
-95.91K
-2.26%
Sep 30, 2025
T. Rowe Price Associates, Inc.
4.10M
3.18%
+2.45M
+148.51%
Sep 30, 2025
Two Sigma Investments, LP
3.92M
3.04%
-320.28K
-7.56%
Sep 30, 2025
Eventide Asset Management, LLC
3.32M
2.58%
-137.63K
-3.98%
Sep 30, 2025
Wellington Management Company, LLP
3.25M
2.52%
+1.33M
+68.96%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
9.3%
Global X Genomics & Biotechnology ETF
7.01%
ARK Genomic Revolution ETF
5.81%
First Trust Nasdaq Lux Digi Health Solutions ETF
5.17%
Invesco Dorsey Wright Healthcare Momentum ETF
4.73%
ROBO Global Healthcare Technology & Innovation ETF
3.53%
State Street SPDR S&P Health Care Services ETF
3.35%
iShares Health Innovation Active ETF
3.27%
Simplify Health Care ETF
2.36%
Alpha Architect U.S. Quantitative Momentum ETF
2.35%
View more
Franklin Genomic Advancements ETF
Proportion9.3%
Global X Genomics & Biotechnology ETF
Proportion7.01%
ARK Genomic Revolution ETF
Proportion5.81%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion5.17%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion4.73%
ROBO Global Healthcare Technology & Innovation ETF
Proportion3.53%
State Street SPDR S&P Health Care Services ETF
Proportion3.35%
iShares Health Innovation Active ETF
Proportion3.27%
Simplify Health Care ETF
Proportion2.36%
Alpha Architect U.S. Quantitative Momentum ETF
Proportion2.35%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Guardant Health Inc?
The top five shareholders of Guardant Health Inc are:
The Vanguard Group, Inc. holds 11.88M shares, accounting for 9.22% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.57M shares, accounting for 6.65% of the total shares.
Baillie Gifford & Co. holds 5.13M shares, accounting for 3.98% of the total shares.
Capital International Investors holds 4.69M shares, accounting for 3.64% of the total shares.
Invesco Advisers, Inc. holds 4.64M shares, accounting for 3.60% of the total shares.
The Vanguard Group, Inc. holds 11.88M shares, accounting for 9.22% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.57M shares, accounting for 6.65% of the total shares.
Baillie Gifford & Co. holds 5.13M shares, accounting for 3.98% of the total shares.
Capital International Investors holds 4.69M shares, accounting for 3.64% of the total shares.
Invesco Advisers, Inc. holds 4.64M shares, accounting for 3.60% of the total shares.
What are the top three shareholder types of Guardant Health Inc?
The top three shareholder types of Guardant Health Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Baillie Gifford & Co.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Baillie Gifford & Co.
How many institutions hold shares of Guardant Health Inc (GH)?
As of 2025Q4, 776 institutions hold shares of Guardant Health Inc, with a combined market value of approximately 125.36M, accounting for 97.30% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.77%.
What is the biggest source of revenue for Guardant Health Inc?
In FY2025Q3, the -- business generated the highest revenue for Guardant Health Inc, amounting to -- and accounting for --% of total revenue.
